ethyl 4-chloro-3-cyanobenzoate | 1261751-27-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-chloro-3-cyanobenzoate
• 英文别名: Ethyl 4-chloro-3-cyanobenzoate
• CAS: 1261751-27-2
• 化学式: C₁₀H₈ClNO₂
• 分子量: 209.632
• InChiKey: XVKUSKQJRYFEHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-chloro-3-cyanobenzoate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 15.0h， 生成 4-chloro-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoic acid
  参考文献：
  名称：

  Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

  摘要：

  Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.056
• 作为产物：
  描述：

  4-氯-3-氰基苯甲酸 在 硫酸 作用下， 以 乙醇 为溶剂， 反应 40.0h， 以55%的产率得到ethyl 4-chloro-3-cyanobenzoate
  参考文献：
  名称：

  Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

  摘要：

  Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.056

文献信息

• XANTHINE OXIDASE INHIBITOR
  申请人：Nishino Takeshi

  公开号：US20090149452A1

  公开（公告）日：2009-06-11

  A compound represented by the following formula (I) is used as a xanthine oxidase inhibitor: in which R 1 is phenyl or pyridyl each optionally having, as a substituent, C 1-8 alkyl, C 1-8 haloalkyl, C 1-8 alkoxy, carboxyl, halogeno, hydroxyl, nitro, cyano, amino, etc.; R 2 is cyano, nitro, etc.; X is oxygen, sulfur, etc.; and Y is sulfur, NH, etc.

  以下式子(I)所代表的化合物被用作黄嘌呤氧化酶抑制剂： 其中，R1为苯基或吡啶基，每个基团都可以选择性地具有C1-8烷基，C1-8卤代烷基，C1-8烷氧基，羧基，卤素，羟基，硝基，氰基，氨基等取代基；R2为氰基，硝基等；X为氧，硫等；Y为硫，NH等。